Tumori Journal Abstract Book - October 2020 - 212

212

Late Breaking Abstracts
DLBA02*
Epidemiology and clinical course
of SARS-CoV-2 infection in cancer
patients in the Veneto Oncology
Network: The ROVID Study
Conte P.1, Zagonel V.2, Chiari R.3, Cattelan A.M.4, Vianello A.5,
Chiarion Sileni V.6, Bassan F.7, Bernardi D.8, Gori S.9, Zustovich F.10,
Milella M.11, Azzarello G.12, Mandarà M.13, Morandi P.14, Oliani C.15,
Pastorelli D.16, Zaninelli M.17, Aprile G.18, Piacentini P.19,
Guarneri V.20
1

Università di Padova, Oncologia Medica 2, Istituto Oncologico Veneto IOV
IRCCS, Padova; 2Oncologia Medica 1 Istituto Oncologico Veneto IOV IRCCS,
Padova; 3Oncologia, Ospedali Riuniti Padova Sud, Padova; 4Malattie Infettive
e Tropicali, Azienda Ospedale Università di Padova, Padova; 5Fisiopatologia
Respiratoria, Azienda Ospedale Università di Padova, Padova; 6Oncologia del
Melanoma e dell'Esofago, Istituto Oncologico Veneto IOV IRCCS, Padova;
7
Oncologia Medica, AULSS7 Pedemontana, Bassano; 8Oncologia Medica,
AULSS4 Veneto Orientale, San Doná di Piave; 9Oncologia Medica, IRCCS
Ospedale Sacro Cuore Don Calabria, Negrar (VR); 10Oncologia Medica,
AULSS1 Dolomiti, Belluno; 11Università di Verona, Oncologia Medica, Azienda
Ospedaliero-Universitaria , Verona; 12Oncologia Medica, AULSS3 Serenissima,
Mirano; 13Oncologia, Ospedale Fracastoro, AULSS9 Scaligera, San Bonifacio;
14
Oncologia Medica, AULSS3 Serenissima, Venezia; 15Oncologia Medica,
AULSS5 Polesana, Rovigo; 16Oncologia Medica, AULSS1 Dolomiti, Feltre;
17
Oncologia Medica, AULSS9 Scaligera, Villafranca; 18Oncologia Medica,
AULSS8 Berica, Vicenza; 19Oncologia Medica, AULSS9 Scaligera, Legnago;
20
Università di Padova, Oncologia Medica 2 Istituto Oncologico Veneto IOV
IRCCS, Padova

Background: COVID-19 pandemic started in Italy with
clusters identified in Northern Italy. Since the beginning,
the Veneto region started a proactive approach, including
testing for SARS-CoV-2 part of the asymptomatic
population and healthcare providers. The Veneto Oncology
Network ROV licensed a dedicated PDTA to ensure proper
care minimizing the risk of infection in cancer patient
(pts). At the same time, a regional registry (ROVID) has
been set up, to describe epidemiology and clinical course
of SARS-CoV-2 infection in cancer pts.
Materials and methods: All pts with cancer diagnosis
and documented SARS-CoV-2 infection are eligible. The
following information are recorded: age, cancer diagnosis,
stage, tumor biology, comorbidities, presence of COVID19 symptoms, anticancer treatment at the time infection
(type, aim, line of therapy, discontinuation, recovery),
other medical treatments, hospitalization, treatments for
SARS-CoV-2 infection, fate of the infection.
Results: 144 pts from 18 centers have been enrolled. Mean
age at the time infection: 69 yrs (25 to 95 yrs). The 5 most
common cancer types were breast cancer (n=26), colorectal, prostate, lung cancer (n=16 each), melanoma (n=10).
Distribution by stage was as follows: I 19%, II 9%, III
13%, IV 59%. Lung metastases were documented in 15%
of the cases. 77% of the pts had at least one comorbidity.
COVID-19 symptoms were reported in 78% of the pts.

Tumori Journal 106(2S)
Active anticancer therapy at the time of the infection was
reported for 71 pts (chemotherapy n=37, targeted therapy
n=14, hormonal therapy n=13, immunotherapy n=6).
Treatment was discontinued because of infection in 44
case. 101 pts were hospitalized; 45 received low flow oxygen support and 26 received non-invasive mechanical ventilation, high flow nasal cannula or endotracheal intubation.
The fate of infection is available for 95 cases so far: 44
infection resolution with confirmed negative swab, 16
with clinical resolution discharged with positive swab, and
35 deaths. Among cases with fatal exitus, 22 were attributable to COVID-19.
Conclusions: Data collection is still ongoing, including
further follow up and results of serological tests, where
available. The mortality rate reported in this study is in line
with other registry of cancer patients, confirming the
frailty of this population. These data reinforce the need to
protect cancer patients from SARS-CoV2 infection.
Supported by research grant from Fondazione Cariparo

ELBA03
Health-related quality of
life, heart rate variability and
physical fitness in breast cancer
patients during the COVID-19
lockdown: the impact of a
lifestyle program ('MoviS Project,
movement and health beyond the
care' (CESU approval n. 21/10.07.2019)
Emili R.1, Natalucci V.2, Ferri Marini C.2, Lucertini F.2, Vallorani L.2,
Sisti D.2, Monaldi S.1, Somaini M.3, Annibalini G.2, De Santi M.2,
Panico A.2, Barocci S.4, Flori M.5, Biancalana V.2, Rocchi M.B.2,
Stocchi V.2, Brandi G.2, Villarini A.6, Catalano V.7, Barbieri E.2
1
U.O.C. Oncologia Medica Ospedale Santa Maria della Misericordia Area
Vasta n. 1, Urbino; 2Department of Biomolecular Sciences, University
of Urbino Carlo Bo, Urbino; 3Fondazione IRCCS Ca' Granda - Ospedale
Maggiore, Policlinico di Milano, Milano; 4U.O.C. Patologia Clinica Ospedale
Santa Maria della Misericordia, Area Vasta n. 1, Urbino; 5U.O.C. Cardiologia
Ospedale Santa Maria della Misericordia, Area Vasta n. 1, Urbino;
6
Department of Research, Epidemiology and Prevention Unit, Fondazione
IRCCS Istituto Nazionale dei Tumori, Milan, Italy, Urbino; 7U.O.C. Oncologia
Medica Ospedale Santa Maria della Misericordia, Area Vasta n. 1, Urbino

Background: Breast cancer (BC) is the most common
invasive cancer in women and evidence has shown that
exercise can significantly improve the outcomes of BC
survivors. MoviS: 'Movement and Health Beyond Care' is
a randomized controlled trial, which aims to educate cancer patients after adjuvant therapy on the benefits of exercise and proper nutritional plan.
Material (patients) and methods: Thirty women with
stage 0-III non-metastatic BC recruited 12-month postsurgery (age: 53.5±7.6; BMI: 25.3±4.9) were randomized
in two groups: intervention arm received 3-month aerobic

Tumori Journal Abstract Book - October 2020

Table of Contents for the Digital Edition of Tumori Journal Abstract Book - October 2020